The Howard Gilman Institute for Valvular Heart Disease
blank top line
home
heart valve disease
patient care
about the institute
research
conference
in the news
contact us
contact us

In the News

PRESS RELEASE | 4-9-2008
JAMA
ARTICLE HIGHLIGHTS LIMITS OF DATA-SHARING BY OVERSIGHT COMMITTEES MONITORING CLINICAL TRIALS OF HEART DISEASE TREATMENTS

The important issue of sharing interim cardiovascular clinical trial data is explored in the article, “When Should Data and Safety Monitoring Committees Share Interim Results in Cardiovascular Trials?” in the April 9th issue of the Journal of the American Medical Association (JAMA). The article is authored by Jeffrey S. Borer, MD (Weill Cornell Medical College), David J. Gordon, MD, Ph.D. and Nancy L. Geller, Ph.D. (both of National Heart, Lung and Blood Institute, National Institutes of Health).

Read the full press release: JAMA Article Highlights Limits of Data-Sharing by Oversight Committees Monitoring Clinical Trials of Heart Disease Treatments

 

PRESS RELEASE | 3-30-2008
NON-INVASIVE MEASUREMENT OF HEART MUSCLE CONTRACTILITY PROVIDES BEST PREDICTOR OF SURVIVAL AFTER AORTIC VALVE REPLACEMENT

At the 57th Annual Scientific Session of the American College of Cardiology (ACC), Dr. Jeffrey S. Borer is presenting the findings of a 28-year study that show that a non-invasively measured contractility descriptor previously used to predict clinical outcomes in patients with aortic regurgitation (AR — leaking aortic valve) without surgery is also a superior measure for determining survival after AR is relieved by aortic valve replacement (AVR).

Read the press release: Non-Invasive Measurement of Heart Muscle Contractility Provides Best Predictor of Survival after Aortic Valve Replacement

 

PRESS RELEASE | 12-28-2007
Dr. Jeffrey S. Borer Urges Improved Drug Regulations to Ensure Heart Safety of Non-Heart Drugs

Current regulatory policies should be strengthened to ensure acceptable cardiovascular safety of drugs developed primarily for non-cardiovascular medical problems, according to a recent presentation made by Dr. Jeffrey Borer, an authority in cardiovascular medicine and surgery at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

His recommendations include earlier testing of all drugs' cardiovascular effects and giving regulatory bodies the authority to mandate continuing evaluation of drug effects, even after approval for marketing.

Read the full press release: Physician-Scientist Urges Improved Drug Regulation to Ensure Heart Safety of Non-Heart Drugs

 

PRESS RELEASE | 10-15-2007
Exercise Tolerance is Good Measure of Likely Progression of Mitral Regurgitation (MR)

A study from the Howard Gilman Institute of Valvular Heart Disease of Weill Cornell Medical College, headed by Dr. Jeffrey S. Borer, shows that exercise tolerance — determined by conventional exercise testing on a treadmill — is a good measure of likely progression to heart failure in patients with leaking mitral heart valves — mitral regurgitation (MR). The study was published in the October 15th issue of the American Journal of Cardiology.

Read the full press release: Excercise Tolerance is Good Measure of Likely Progression of Mitral Regurgitation (MR)

 

 

 

 

blank
heart valve disease | patient care | about the institute | research | conference | news | contact us
The Howard Gilman Institute for Heart Valve Disease